Lorazepam Dosing for Alcohol Withdrawal Syndrome
For acute alcohol withdrawal syndrome, start lorazepam at 1-4 mg every 4-8 hours (oral, IV, or IM), with a total daily dose of 6-12 mg/day, then taper based on symptom resolution. 1
Specific Dosing Algorithm
Initial Dosing
- Standard regimen: 1-4 mg every 4-8 hours via oral, IV, or IM routes 1
- Total daily dose: 6-12 mg/day divided into multiple doses 1
- Tapering: Gradually reduce dose following resolution of withdrawal symptoms 1
When to Choose Lorazepam Over Long-Acting Benzodiazepines
Lorazepam is specifically recommended for patients with:
- Severe AWS 1
- Advanced age 1
- Recent head trauma 1
- Liver failure 1, 2
- Respiratory failure 1
- Other serious medical comorbidities 1
- Obesity 1
The rationale is that lorazepam is an intermediate-acting benzodiazepine with no active metabolites and undergoes glucuronidation rather than hepatic oxidation, making it safer in hepatic dysfunction 2.
Dosing Strategies: Fixed vs. Symptom-Triggered
Symptom-triggered regimens are superior to fixed-dose schedules 2. Research demonstrates that symptom-triggered lorazepam treatment results in:
- Significantly lower total medication doses (9.5 mg vs. 19.9 mg) 3
- Shorter treatment duration (47.8 hours vs. 146 hours) 3
- Equal safety profile with no difference in seizures or delirium tremens 3
Practical Implementation
- Use CIWA-Ar scores to guide dosing (though not for diagnosis) 1
- Administer lorazepam when CIWA-Ar score >8 (moderate AWS) or ≥15 (severe AWS) 2
- Reassess frequently and adjust based on symptom control
Critical Safety Considerations
Administration Requirements
Prior to IV use, lorazepam MUST be diluted with an equal amount of compatible diluent 4. IV injection should be:
- Made slowly (2 mg/min for status epilepticus dosing) 4
- With repeated aspiration 4
- Stopped immediately if patient complains of pain (risk of intra-arterial injection) 4
Respiratory Monitoring
- Airway patency must be assured and respiration monitored closely 4
- Equipment for ventilatory support should be readily available 4
- Risk of respiratory depression increases with concurrent CNS depressants 4
Duration Limitations
Avoid benzodiazepine use beyond 10-14 days due to abuse potential 2. Patients with alcohol use disorder are at higher risk for benzodiazepine dependence 2, 4.
Essential Adjunctive Treatment
Thiamine must be given to ALL patients with AWS:
- Dose: 100-300 mg/day 1
- Duration: Maintain for 2-3 months following resolution of withdrawal symptoms 1
- Critical timing: Administer thiamine BEFORE IV fluids containing glucose to prevent precipitating acute Wernicke encephalopathy 1
Comparative Effectiveness
While lorazepam and chlordiazepoxide show similar efficacy in preventing delirium tremens (7% vs. 9%, p=0.76) 5, patients treated with chlordiazepoxide required significantly more PRN benzodiazepine (6.6 mg vs. 3.2 mg lorazepam equivalents, p=0.03) 5. This suggests lorazepam may provide more consistent symptom control.
Lorazepam is equally effective as diazepam in reducing AWS symptoms 6, but has pharmacokinetic advantages including no active metabolites and more predictable absorption, particularly important in patients with hepatic dysfunction.
Common Pitfalls to Avoid
Do not use CIWA-Ar for diagnosis - high scores can occur in anxiety disorders, sepsis, hepatic encephalopathy, and severe pain 1
Do not underdose in severe AWS - inadequate initial control increases risk of progression to delirium tremens
Do not forget psychiatric consultation - recommended for evaluation, acute management, and long-term abstinence planning (A1 recommendation) 1
Do not discharge patients prematurely - sedative effects may persist 24-48 hours, particularly in patients >50 years 4
Monitor for protracted withdrawal - symptoms can persist weeks to >12 months after discontinuation 4